Last update 15 May 2025

BMS-986403

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BMS 986403, BMS-986403, BMS986403
Target-
Action-
Mechanism-
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Chronic Lymphocytic Leukemia
Inactive Indication
B-Cell LymphomaRecurrent Chronic Lymphoid LeukemiaSmall Lymphocytic Lymphoma
Originator Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Inactive Organization-
License Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with BMS-986403
NCT05244070
/ TerminatedPhase 1
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
100 Clinical Results associated with BMS-986403
Login to view more data
100 Translational Medicine associated with BMS-986403
Login to view more data
100 Patents (Medical) associated with BMS-986403
Login to view more data
100 Deals associated with BMS-986403
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell LymphomaPhase 1
United States
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Sep 2022
B-Cell LymphomaPhase 1
Spain
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Sep 2022
Recurrent Chronic Lymphoid LeukemiaPhase 1
United States
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Sep 2022
Recurrent Chronic Lymphoid LeukemiaPhase 1
Spain
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Sep 2022
Small Lymphocytic LymphomaPhase 1
United States
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Sep 2022
Small Lymphocytic LymphomaPhase 1
Spain
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
14 Sep 2022
Chronic Lymphocytic LeukemiaPreclinical
Canada
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
17 Feb 2022
Chronic Lymphocytic LeukemiaPreclinical
Europe
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
17 Feb 2022
Chronic Lymphocytic LeukemiaPreclinical
United Kingdom
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
17 Feb 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free